McDermott advises PDC*line in license agreement with LG Chem for lung cancer therapeutic vaccine


McDermott Will & Emery advised PDC*line in connection with the signing of a licensing agreement with the Korean pharmaceutical group LG Chem, to develop its therapeutic vaccine against lung cancer in Asia, for a total amount of 108 million euros.

Under the terms of the agreement, the Liège-based biotech PDC*line Pharma will collaborate with LG Chem Life Sciences, the life sciences division of the major conglomerate LG, which will have full rights to development and market the drug candidate for South Korea, as well as an exclusive option in other Asian countries development and marketing rights of the drug candidate for South Korea, along with an exclusive option in other Asian countries.

McDermott Will & Emery advised PDC*Line Pharma with a team composed of Partner Emmanuelle Trombe, and Katya Ascher on corporate aspects, Partner Antoine Vergnat, and Côme de Saint-Vincent on tax aspects.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts